Schott Pharma AG KGaA (MIL:1SXP) Other Current Liabilities: €110.8 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MIL:1SXP Schott Pharma AG & CO KGaA MIL:1SXP
63 GF Score
Price €21.00
GF Value €28.18
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Schott Pharma AG KGaA Other Current Liabilities?

Schott Pharma AG KGaA MIL:1SXP 63 Other Current Liabilities is €110.8 Mil as of Mar. 2026. GuruFocus rates MIL:1SXP with a GF Score™ of 63/100 and a GF Value™ of €28.18 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Schott Pharma AG KGaA's other current liabilities for the quarter that ended in Mar. 2026 was €110.8 Mil.

Schott Pharma AG KGaA's quarterly other current liabilities declined from Sep. 2025 (€100.1 Mil) to Dec. 2025 (€93.7 Mil) but then increased from Dec. 2025 (€93.7 Mil) to Mar. 2026 (€110.8 Mil).

Schott Pharma AG KGaA's annual other current liabilities declined from Sep. 2023 (€96.5 Mil) to Sep. 2024 (€96.3 Mil) but then increased from Sep. 2024 (€96.3 Mil) to Sep. 2025 (€100.1 Mil).

Schott Pharma AG KGaA Other Current Liabilities Related Terms

Schott Pharma AG KGaA Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Schott Pharma AG KGaA's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Schott Pharma AG KGaA Other Current Liabilities Chart

Schott Pharma AG KGaA Annual Data
Trend Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Other Current Liabilities
Get a 7-Day Free Trial 62.99 84.15 96.51 96.31 100.07

Schott Pharma AG KGaA Quarterly Data
Sep20 Sep21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 101.42 109.47 100.07 93.69 110.76
MIL:1SXP
63GF Score
Schott Pharma AG & CO KGaA MIL:1SXP
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Schott Pharma AG KGaA Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of €110.8 Mil mean?
Schott Pharma AG KGaA (MIL:1SXP) has a Other Current Liabilities of €110.8 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Schott Pharma AG KGaA.
Is Schott Pharma AG KGaA's Other Current Liabilities too high?
Schott Pharma AG KGaA's current Other Current Liabilities is €110.8 Mil. Overall, Schott Pharma AG KGaA has a GF Score™ of 63/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Schott Pharma AG KGaA's Other Current Liabilities compare to ISRG and BDX?
Schott Pharma AG KGaA's Other Current Liabilities of €110.8 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Medical Devices & Instruments company?
A good Other Current Liabilities depends on the Medical Devices & Instruments industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Schott Pharma AG KGaA. Schott Pharma AG KGaA's current Other Current Liabilities is €110.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Schott Pharma AG KGaA stock overvalued right now?
Based on GuruFocus' analysis, Schott Pharma AG KGaA (MIL:1SXP) is currently considered Modestly Undervalued. The stock's GF Value™ is €28.18, compared to a current price of €21.00 — trading 25.5% below its estimated fair value. The current Other Current Liabilities is €110.8 Mil. Schott Pharma AG KGaA's overall GF Score™ is 63/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Schott Pharma AG KGaA (MIL:1SXP), the current Other Current Liabilities is €110.8 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Schott Pharma AG KGaA (MIL:1SXP) Overvalued in 2026?

Based on GuruFocus' analysis, Schott Pharma AG KGaA stock appears to be undervalued. The current stock price of €21.00 is trading 25.5% below its estimated GF Value™ of €28.18. GuruFocus considers Schott Pharma AG KGaA to be Modestly Undervalued.

Key valuation signals for MIL:1SXP:

  • Other Current Liabilities: €110.8 Mil
  • GF Value™: €28.18 vs. price of €21.00 (25.5% below fair value)
  • GF Score™: 63/100 with 2 warning signs

No single metric tells the full story. See the MIL:1SXP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Schott Pharma AG KGaA Business Description

Other Exchanges 1SXP:Germany1SXP:Austria
Address Hattenbergstrasse 10, Mainz, RP, DEU, 55122
Schott Pharma AG & CO KGaA is an international provider of drug containment solutions and delivery systems for injectable drugs for pharma, biotech and life-sciences. Its business operates in two segments: Drug Containment Solutions (DCS) and Drug Delivery Systems (DDS). The majority of revenue is being generated from the DCS segment, which includes products like vials, cartridges, and ampoules, and provides customers with sterile and non-sterile options in standard and high-end formats for drug storage. Geographically, the company generates revenue from Europe, the Middle East, Africa (EMEA), Asia and the South Pacific, North America, and South America.
63GF Score

Get the complete analysis for MIL:1SXP

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€21.00
Price
€28.18
GF Value